Myeloma Patients Europe

08/12/2025

Excited to be sharing our latest research at !

Over 1,000 myeloma patients and family carers across 22 countries told us how they feel about where and how they receive their treatment.

Our findings show treatments impact more than clinical outcomes - they shape daily routines, emotional well-being, and quality of life of patients and families. Where and how treatment is delivered matters. It can increase the burden on patients and families, so treatment planning must prioritise their needs and support shared decision-making.

We'll be sharing more on this research and it's outputs soon!

08/12/2025

New trial dual-targeting CAR-T therapy for myeloma has positive results!

The Durga-1 trial evaluates safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, unlike current CAR-T therapies that target only BCMA, AZD0120 targets both BCMA and CD19 antigens.

This dual approach could help reduce the risk of antigen-negative relapses—when cancer returns without the targeted antigen.

Watch Dr. Shambavi Richard, explain more in this video who leads the trial which was presented at American Society of Hematology (ASH) Annual Congress, in Orlando, Florida, US.

The Durga-1 trial evaluates safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma. Dr. Shamb...

07/12/2025

CAMMA 3 trial results are out! Watch this video with Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the University of Sydney, Australia, who has just presented this study at . CAMMA 3 shows manageable safety and meaningful clinical activity of subcutaneous cevostamab in relapsed/refractory myeloma (RRMM).

https://youtu.be/H6EtYJ9xJ7g

Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of Sydney, Australia, explains for Myeloma Patients Europe (MPE) the first results from the ph...

07/12/2025

The American Society of Hematology (ASH) Annual Congress continues today with more sessions and updates on blood diseases. Yesterday, we had the opportunity to hear new data in myeloma, including results from the GEM-CESAR clinical trial, a study assessing early rescue treatment with daratumumab, pomalidomide and dexamethasone (DPd) in people with high-risk smoldering myeloma.

Watch here the key results explained by Dr. Bruno Paiva, Clínica Universidad de Navarra, Spain.

Dr. Bruno Paiva, Clínica Universidad de Navarra, explains the main results of the GEM-CESAR clinical trial presented at the American Society of Hematology (A...

05/12/2025

MPE is attending the annual congress in Orlando, Florida. Over the next few days, we will follow the key updates in and and speak with leading experts to understand what they mean for patients.

And if you want to follow further, we'll be hosting a post-ASH webinar, on Wednesday 17 December, focusing on myeloma and AL amyloidosis, which you can still sign up for now.

https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/

05/12/2025

REMINDER - The Rare Barometer survey on what helps people live with a rare or undiagnosed condition will close on 14 December.

This survey is available in 25 languages and is open to any country, so please give 20 minutes of your time to fill in the question or share with your own networks, as there is not much time left to take part.

This has been organised by

Choose your language and take part before Sunday 14 December
tiny.cc/RB-MH

03/12/2025

Pain management is an important part of myeloma care. There's no need to suffer in silence - if you are experiencing pain, tell your healthcare team.

There are many options available to help manage pain and improve your quality of life. You deserve to be comfortable.

02/12/2025

Our Year in Review 2025 is here!

This year, we strengthened partnerships, welcomed new members, and made progress on the issues that matter most to myeloma and AL amyloidosis patients across Europe. Each achievement reflects the dedication of our community—patients, families, clinicians, researchers and advocates working as one.

Thanks to all those who have helped and supported our mission throughout 2025!

Explore our interactive Year in Review 2025 now: https://www.canva.com/design/DAG4rkR6fsc/-YYNla2qbvVQbSViIY7BhA/view?utm_content=DAG4rkR6fsc&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=hf81b8f913a

01/12/2025

Did you know that approximately 50,000 people are diagnosed with myeloma across Europe each year?
Behind this number are thousands of individuals and families who are also affected by this diagnosis.

This is why we advocate for patients and families affected by myeloma.

25/11/2025

MPE is excited to announce the launch of the SISAQOL-IMI recommendations which set out clear and consensus-based standards for the design, analysis and reporting of quality of life in cancer research. These recommendations are published in the Lancet Oncology.
The recommendations should lead to more consistent, interpretable and understandable cancer quality of life data.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00520-0/abstract
The standards are the result of 5 years of work, led by the EORTC - European Organisation for Research and Treatment of Cancer, involving representatives from academia, regulatory bodies, the pharmaceutical industry, health technology assessment bodies and patient organisations. MPE, in collaboration with our patient community and WECAN - Workgroup of European Cancer Patient Advocacy Networks, has been working to ensure patient involvement at every stage of the project. Whilst at times complex, it has been a rewarding experience to contribute to this important work which we hope will improve patient access to medicines that both improve their survival and how well they live with their disease.

Discover the resources at https://www.sisaqol-imi.org/outputs/

hashtag hashtag hashtag hashtag

Interactive table with recommendations The SISAQOL-IMI webtool provides researchers with an interactive platform for accessing the SISAQOL-IMI recommendations that support complex decisions related to study design, data analysis, and results communication when incorporating patient-reported outcomes...

25/11/2025

Great work!

22/11/2025

MPE member organisation Associação Portuguesa Contra a Leucemia held its 6th Annual Congress today in Lisbon, Portugal. The event brought together a diverse group of participants, including patients, haematologists, patient advocates, and other key stakeholders.
This year’s programme featured a wide range of sessions, covering topics such as CAR-T and precision medicine in Portugal, current realities and future innovation, the role of patients and patient organisations in oncology policy, the importance of collaboration and referral pathways, equitable access to treatment and care and even sessions on physical activity.
Aligned with MPE’s strategic goal to strengthen and empower its members to better support patients and amplify advocacy efforts, MPE was pleased to participate and show its support. Linda Christopher, MPE’s Head of Member and Patient Community Programmes, attended the congress to engage with the national patient and haematology community, as well as to present an MPE poster on shared decision-making.
It was an exceptionally well-organised event, and MPE congratulates APCL for their tremendous effort in delivering such a valuable congress. We wish APCL every success in their future endeavours.